Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for reduction of myocardial injury biomarkers in acute coronary syndrome
IRCT20111206008307N36Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allopurinol in acute coronary syndrome (ACS) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Cardiac troponin I and CK-MB enzyme. Started Nov 2019; status: completed.
02
Drugs
allopurinol
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20111206008307N36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N36.